NasdaqGM:FLGTHealthcare
Assessing Fulgent Genetics (FLGT) Valuation After Earnings Outperformance And AI Oncology Pipeline Progress
Fulgent Genetics (FLGT) is back on investors’ radar after its latest update, with 2025 earnings showing US$322.67 million in sales, a wider net loss, and fresh 2026 revenue guidance of about US$350 million.
See our latest analysis for Fulgent Genetics.
The share price reaction has been sharp, with a 1 day share price return of a 38.09% decline and a year to date share price return of a 40.09% decline, even though the 1 year total shareholder return is roughly flat. This suggests recent...